Catena Pharmaceuticals catenapharma.com


Public list: Pharma Startups (6570) Cancer Therapeutics (1180)

Catena Pharmaceuticals is focused on the development and commercialization of GPCR antagonists, particularly in the areas of cancer and fibrotic disease. Catena's chemistry is capable of affecting a specific class of GPCRs known to be relevant in a variety of disease states.

Catena Pharmaceuticals is focused on the development and commercialization of GPCR antagonists, particularly in the areas of cancer and fibrotic disease. Catena's chemistry is capable of affecting a specific class of GPCRs known to be relevant in a...Show all

Company (Alive / Active)

Phone: 888-265-1353

Fax:

2530 Meridian Parkway
Suite 200
Durham, 27713
North Carolina, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Catena Pharmaceuticals $0M Oct 20, 2008
See all 16 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Catena Pharmaceuticals Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 1 investors

Competitors

Company Status Description Investors

Inimex Pharmaceuticals

Vancouver, British Columbia, Canada
Alive / ActiveInimex Pharmaceuticals, Inc. is focused on the development and commercialization of Innate Defense Regulators (IDRs), first in class drugs that selectively trigger the body's innate defenses without causing inflammation. IDR products have major market potential for infectious disease, cancer, and inflammatory disease. These products will reduce morbidity and mortality in the rapidly growing population of immune suppressed and elderly patients who are "at-risk" for these disorders. IDR produc...Show allLogin to see details

Akebia Therapeutics

Cambridge, Massachusetts, United States
IPO / Went publicAkebia Therapeutics is focused on discovering and developing therapeutic solutions leveraging the potential of the hypoxia-inducible factor - or HIF - biology. HIF-Prolyl Hydroxylase inhibition could represent an approach to treating certain conditions where there is an unmet need.Login to see details
See all 16 competitors

Patents

Title Application Date Patent Date Status
(Patent / Application)